Mercer Global Advisors Inc. ADV Takes $624,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Mercer Global Advisors Inc. ADV acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, Holdings Channel.com reports. The firm acquired 7,471 shares of the biopharmaceutical company’s stock, valued at approximately $624,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC lifted its stake in shares of Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC lifted its stake in shares of Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after purchasing an additional 8,440 shares during the period. Principal Financial Group Inc. increased its position in Intra-Cellular Therapies by 3.3% in the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after buying an additional 18,865 shares in the last quarter. Finally, Merit Financial Group LLC bought a new stake in Intra-Cellular Therapies in the 4th quarter valued at about $206,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on ITCI. Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their target price for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, StockNews.com began coverage on Intra-Cellular Therapies in a research report on Wednesday, May 7th. They issued a “hold” rating for the company. Eleven investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $109.70.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Monday. The company has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The business has a 50-day simple moving average of $131.73 and a two-hundred day simple moving average of $112.40.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.